Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Peptide Therapeutics Market to Outstrip $50,003.15 Million by 2027 Growing Sturdy at 9.2% CAGR – COVID-19 Impact and Global Analysis by TheInsightPartners.com

Published

on

Pune, India., June 09, 2021 (GLOBE NEWSWIRE) — Peptide Therapeutics Market: Key Insights
According to our new research study on “Peptide Therapeutics Market to 2027 – Global Analysis and Forecast – by Type, Route of administration, Synthesis Technology, and Application,” the Peptide Therapeutics Market Size was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027; it is expected to grow at a CAGR of 9.2% during 2020–2027.

Peptide Therapeutics Market: Competition Landscape and Key Developments
Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and GlaxoSmithKline PLC are among the key companies operating in the peptide therapeutics market. Leading players are focusing on the new product launch, expansion and diversification of their market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.

In December 2020, Novo Nordisk submitted a label extension application to the European Medicines Agency (EMA) for the existing marketing authorization for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg.

Get Exclusive Sample Pages of Peptide Therapeutics Market – COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00003793/

In June 2019, Eli Lilly and Company received FDA approval for its Emgality, a calcitonin gene-related peptide (CGRP) antibody for the treatment of migraine and episodic cluster headache.

In 2019, North America dominated the global peptide therapeutics market. The market growth in the region is attributed to growing awareness regarding peptide-based drugs, increasing investments in drug discovery, and rising demand for alternative therapies for chronic disease management. In December 2020, investors from PayPal Holdings Inc. invested US$ 35.4 million in US-based biotechnology company Peptilogics Inc. The company is engaged in the development of peptide-based therapeutics for the treatment of chronic conditions. At present, company’s drug candidate PLG0206 is in phase 2 of clinical trials for the treatment of prosthetic joint infections. Moreover, in October 2019, Pepticom, an artificial intelligence (AI) based pharmaceutical company raised US$ 5.0 million through the rounds of series funding. The company is planning to utilize these financial resources to accelerate the development of an AI-based platform to leverage the peptide drug discovery. Such developments are estimated to catalyze the drug development and discoveries, which will eventually offer a favorable environment for North America peptide therapeutics market during the forecast period.

Based on type, the peptide therapeutics market is segmented into generic and innovative. The innovative segment held ~67.83% of the market share in 2019. In terms of route of administration, the peptide therapeutics market is segmented into parenteral, oral, mucosal, pulmonary, and others. The parenteral segment held the largest share of the market in 2019, and oral segment is anticipated to register the highest CAGR in the market during the forecast period.

Download Sample PDF Brochure of Peptide Therapeutics Market Growth Research Report at https://www.theinsightpartners.com/sample/TIPRE00003793/

Based on synthesis technology, the peptide therapeutics market was segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2019, and hybrid technology segment is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the peptide therapeutics market is segmented into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2019.

Strong Pipeline and Applications of Peptide Drugs Fuel Peptide Therapeutics Market Growth:
The effectiveness of peptide-based drugs over cancer and other disorders is actively attracting huge investments by market players. These investments are leading to development of new therapeutic platforms, which is responsible for robust pipeline of peptide therapeutics. In addition, ongoing studies associated with the applications of peptides are also expected to have a positive impact on the pipeline, which is offering a lucrative opportunity for growth of the market. For instance, in December 2020, Clovis Oncology, Inc. announced the submission of its new drug application, FAP-2286. The company is developing this new drug-based peptide under peptide-targeted radionuclide therapy (PTRT) development program. Moreover, the new candidate is likely to be utilized for diagnosis of fibroblast activation protein (FAP)-positive tumors. In addition, in November 2019, NervGen Pharma Corp. received funding of US$ 1.5 million from its drug-manufacturing partner CSBio in order to boost the clinical research of its NVG-291, a peptide-based drug candidate for the treatment of multiple sclerosis and spinal cord injuries. Moreover, companies are also focusing on the establishment of strategic partnerships in order to boost the peptide production. For instance, in October 2020, Fujitsu Limited and PeptiDream Inc. entered into strategic collaboration for research on peptide candidates. The collaboration is planning to utilize digital annealer technologies to streamline the drug discovery with the help of peptides. Such developments are anticipated to offer a favorable environment for the market growth during the forecast period.

Direct Purchase Copy of Peptide Therapeutics Market Research Study at https://www.theinsightpartners.com/buy/TIPRE00003793/

Peptide Therapeutics Market: Segmental Overview
Based on type, the peptide therapeutics market is segmented into innovative and generic. In 2019, the innovative segment accounted for higher share of the market. Growth of this segment is majorly attributed to increasing investments in peptide research and development and growing number of product approvals. For instance, Novo Nordisk’s Ozempic (semaglutide) received US Food and Drug Administration (FDA) approval in January 2020. It is used to reduce the risk of cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes. Moreover, the rising number of research collaborations among market players is estimated to offer favorable environment for the segment growth.

Browse Related Reports:
Peptide Hormones Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type (Follicle-stimulating Hormone and Luteinizing Hormone, Adrenocorticotropic Hormone, Growth Hormones, Erythropoietin, Insulin); Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, Others), and Geography – https://www.theinsightpartners.com/reports/peptide-hormones-market

Peptide Synthesis Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Reagents, Synthesizers, and Chromatography); Therapeutic Area (Cardiovascular Disorder, Cancer, Respiratory Disorder, Metabolic Disorder, Dermatology, and Others); End User (Pharmaceutical and Biotechnological Companies, Contract Research Organizations (CRO’s), Academic and Research Institutes, and Others), and Geography – https://www.theinsightpartners.com/reports/peptide-synthesis-market

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876

Press Release – https://www.theinsightpartners.com/pr/peptide-therapeutics-market

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending